DexCom
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, DexCom sits in the top decile of US sponsors by registered trial count (#604 of 15,742 sponsors by registered trial count).
DexCom: 26 sponsored US clinical trials, 1 recruiting.
DexCom sponsors 26 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 23 completed. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Diabetes, with 3 trials.
Top-decile sponsor footprint
DexCom ranks in the top decile of sponsors by registered trial count (#604 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
23 of 23 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
26 total, page 1 of 1
Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry (Dexcom Global Registry)
NCT06483945
CONtiNuous glucosE Monitoring (CGM) in People wiTh Type 2 Diabetes Not on Insulin
NCT06601166
Evaluation of Basal Insulin Initialization and Titration in People With Type 2 Diabetes Wearing a Dexcom G6 Sensor
NCT07681375
Remote Monitoring of Vital Signs With Telehealth to Prevent Readmissions for Dysglycemia
NCT05746286
Evaluation of the Safety and Effectiveness of the Dexcom Continuous Glucose Monitoring (CGM) System
NCT04794478
Evaluation of Modified Adhesives With Dexcom G6 Sensor
NCT04840446
Assessing Non-adjunctive CGM Safety at Home and in New Markets
NCT04585139
Glucose Risk Assessment in Employer Populations
NCT04529824
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
NCT03620357
Type 2 Diabetes (T2D) Basal Insulin Users: The Mobile Study (MOBILE)
NCT03566693
Evaluation of the Dexcom G6 Continuous Glucose Monitoring System With a Non-Interferent Sensor
NCT03087877
Effectiveness and Safety of the Dexcom™ G6 Continuous Glucose Monitoring System
NCT02880267
G5® Mobile Continuous Glucose Monitoring System Automated vs. Manual Sensor Applicator
NCT02696252
Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes
NCT02282397
Effectiveness and Safety Study of the Dexcom G4 Platinum With Modified Algorithm
NCT02087995
Observational Study to Evaluate the Effectiveness and Safety of the Dexcom G4 Continuous Glucose Monitoring System in Pediatrics
NCT02363907
Effectiveness and Safety of the Dexcom™ G4 Continuous Glucose Monitoring System in Pediatric Subjects With Diabetes Mellitus
NCT01667185
Evaluation of Glycemic Control Using Adjunctive Continuous Glucose Monitoring With the Dexcom G4 System
NCT01627210
Long-term Use: CGM System Assessment in Adult Athletes With Diabetes Mellitus
NCT01627184
Effectiveness and Safety Study of the Dexcom G4™ Continuous Glucose Monitoring System
NCT01514292
Observational Study to Evaluate the Effectiveness and Safety Study of the Dexcom G4™ Continuous Glucose Monitoring System
NCT01514305
Effectiveness and Safety Study of the DexCom™ G4 Continuous Glucose Monitoring System in Children and Adolescents With Type 1 Diabetes Mellitus
NCT01185496
Pivotal Study of the Intravenous Blood Glucose (IVBG) System, In-Clinic Setting
NCT00925080
Efficacy of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes Mellitus on Multiple Daily Injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) Therapy
NCT01104142
Concurrent Use of Two Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes Mellitus (T1DM)
NCT00939289
Effectiveness and Safety Study of the Next-Generation DexCom™ SEVEN® Continuous Glucose Monitoring System
NCT00722241
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Therapeutic Areas
What is open in the DexCom pipeline
1 recruiting of 26 indexed (4% open); 23 completed (88%).
Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).
Top condition: Diabetes (3 trials), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
DexCom: open-pipeline peers nationwide
Peers matched on 26 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
DexCom sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 26 trials (± recruiting share)
- Abbott Diabetes Care · 26 trials · 12% recruiting
- Aldeyra Therapeutics · 26 trials · 4% recruiting
- California Polytechnic State University-San Luis Obispo · 26 trials · 19% recruiting
- Harvard Medical School (HMS and HSDM) · 26 trials · 15% recruiting
Sponsors near 4% open enrollment (± trial volume)
- MaineHealth · 4% recruiting · 26 trials
- Medtronic Spinal and Biologics · 4% recruiting · 26 trials
- Oklahoma State University · 4% recruiting · 26 trials
- ViiV Healthcare · 4% recruiting · 182 trials
Related
What to do with this DexCom page
26 registered trials is a research-attention snapshot, not an endorsement of DexCom or any single study.
- 1 of DexCom's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Diabetes is the condition DexCom studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetes trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
DexCom pipeline card: 26 registered trials from official public datasets.Report a data error.